Talicia ® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to clarithromycin-based therapies Talicia ® is targeting an estimated two million U.S. ...
Phase 2/3 study process initiated in Brazil and Mexico The global Phase 2/3 study with opaganib in patients with severe COVID-19 has already been approved in the UK and Russia Enrollment planned to be initiated this month - 270 subjects to be enrolled in up to 40 clinical sites Potential ...
TEL-AVIV, Israel and RALEIGH, N.C. , July 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, announced today it is seeking regulatory review by the Securities and Exchange Commission (“SEC”), and intends to ...
Clinical Trial Application approved in Russia for the Phase 2/3 study with opaganib in severe COVID-19 patients following recent approval in the UK and similar submission in Italy -- The Phase 2/3 study aims to enroll 270 subjects in up to 40 clinical sites; enrollment planned to be initiated later ...
TEL-AVIV, Israel and RALEIGH, N.C. , July 01, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Gilead Raday , RedHill's Chief Operating Officer, will present the Company’s ongoing Phase 2/3 ...
The Phase 2/3 multi-center, randomized, double-blind, parallel-arm, placebo-controlled study with opaganib aims to enroll 270 severe COVID-19 patients in up to 40 clinical sites across the UK , Italy , Russia and additional countries -- In parallel, a U.S. ...
Analysis of treatment outcomes in five severe COVID-19 patients showed substantial benefit to patients treated with opaganib under compassionate use in both clinical outcomes and inflammatory markers as compared to a matched case-control group from the same hospital -- All patients in the ...
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study with opaganib in 270 severe COVID-19 patients is planned to be conducted in up to 40 clinical sites across Russia , Italy , the UK and additional countries -- In parallel, a clinical study of ...
TEL-AVIV, Israel and RALEIGH, N.C. , June 18, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Guy Goldberg , RedHill's Chief Business Officer, will present a corporate overview at the Virtual ...
The multi-center, randomized, double-blind, parallel-arm, placebo-controlled Phase 2/3 clinical study of opaganib for severe COVID-19 patients is planned to be conducted in Russia and additional European and other countries -- In parallel, a Phase 2a clinical study of opaganib for severe COVID-19 ...
Menu